|
Pathogen
|
Vaccine Envisaged
|
Target Population
|
Probability of Development
|
Cost of Development ($ millions)
|
Total Time to Steady State of Vaccine Use
|
Total Time to Steady-State Yield of Benefits (years)
|
Predicted Protective Efficacy a
|
Anticipated Utilization
|
Cost of Vaccine Preventable Illness a ($ millions)
|
|
Bordetella pertussis
|
Acellular
|
Infants
|
0.9
|
10
|
4
|
7
|
—
|
0.95
|
—
|
|
Coccidioides immitis
|
Killed spherule preparation
|
High-risk individuals residing or working in endemic areas
|
0.5
|
10
|
16.5
|
51.5
|
0.7
|
0.005
|
49.5
|
|
Cytomegalovirus
|
Attenuated live virus
|
Seronegative (SN) bone marrow and organ transplant recipients and SN persons with leukemias and lymphomas
|
0.5
|
10
|
6
|
7
|
0.7
|
0.95
|
30
|
|
|
|
Nonpregnant adolescent females
|
0.5
|
10
|
17
|
27
|
0.8
|
0.04
|
392
|
|
|
Glycoprotein produced by recombinant DNA technology
|
All children
|
0.5
|
45
|
13.5
|
36.5
|
0.8
|
0.46
|
824.1
|
|
Hemophilus influenzae type b
|
Conjugated polysaccharide
|
Infants
|
0.9
|
30
|
6
|
8
|
0.8
|
0.76
|
395
|
|
Hepatitis A virus
|
Attenuated live virus
|
Susceptibles of all ages (routine for children)
|
0.95
|
15
|
9
|
29
|
0.9
|
0.12
|
104.6
|
|
|
Subunit
|
Susceptibles of all ages (routine for children)
|
0.95
|
25
|
10
|
30
|
0.9
|
0.04
|
104.6
|
|
Hepatitis B virus
|
Glycoprotein produced by recombinant DNA technology
|
High-risk groups (health professionals, homosexuals, IV drug users, etc.)
|
0.95
|
10
|
6.5
|
21.5
|
0.9
|
0.89
|
145.1
|
|
Herpes simplex viruses 1 & 2
|
Glycoprotein produced by recombinant DNA technology
|
Children up to age 12 and older Susceptibles
|
0.9
|
30
|
10
|
30
|
0.45
|
0.36
|
310.4
|
|
|
Attenuated live virus
|
Children up to age 12 and older Susceptibles
|
0.5
|
30
|
18
|
38
|
0.65
|
0.24
|
310.4
|
